2/13
09:25 am
tlsi
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Lake Street Capital. They set a "buy" rating on the stock.
Low
Report
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Lake Street Capital. They set a "buy" rating on the stock.
2/3
04:05 pm
tlsi
TriSalus Life Sciences Announces Key Appointments to Board of Directors
Low
Report
TriSalus Life Sciences Announces Key Appointments to Board of Directors
2/3
08:40 am
tlsi
TriSalus Life Sciences announces drawdown of $10M under credit agreement with OrbiMed [Seeking Alpha]
Low
Report
TriSalus Life Sciences announces drawdown of $10M under credit agreement with OrbiMed [Seeking Alpha]
2/3
08:36 am
tlsi
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed [Yahoo! Finance]
Low
Report
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed [Yahoo! Finance]
2/3
08:00 am
tlsi
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
Low
Report
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
1/24
12:16 pm
tlsi
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $11.00 price target on the stock.
Low
Report
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $11.00 price target on the stock.
1/23
08:00 am
tlsi
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
Medium
Report
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
1/9
08:00 am
tlsi
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
Medium
Report
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
1/8
09:09 am
tlsi
TriSalus Life Sciences names new finance chief [Seeking Alpha]
Medium
Report
TriSalus Life Sciences names new finance chief [Seeking Alpha]
1/8
08:00 am
tlsi
TriSalus Announces Leadership Changes
Medium
Report
TriSalus Announces Leadership Changes
12/17
08:54 am
tlsi
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.
Medium
Report
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.